Differences

This shows you the differences between two versions of the page.

--- home:diseases:psoriasis [08.30.2012] – paulalbert
+++ home:diseases:psoriasis [08.30.2012] – paulalbert
@@ Line 1: / Line 1: @@
-<IncompleteNotice>
 ====== Psoriasis ======
+Psoriasis is an autoimmune disease that affects the skin that varies in severity from minor localized patches to complete body coverage. The richness of the skin microbiome and the emerging discrepancies between the microbial composition between health and disease point to a microbial etiology for psoriasis.
+The Marshall Protocol treats psoriasis by reactivating the innate immune response. In the course of treatment, patients' disease symptoms may become worse due to a process called immunopathology.
-==== L-forms ====
+===== Skin microbiome =====
+{{section>:home:symptoms:skin#skin_microbiome&noheader&firstseconly}}
+[{{ :home:diseases:2010-proal-slovenia.002.jpg|**Patients with psoriasis have different populations of microbes on their skin**}}]
 ===== Evidence of infectious cause =====
+  * **cell wall deficient bacteria** – In a 2009 study, Wang investigated the carriage rate of cell wall deficient bacteria in the tonsil or pharynx of psoriasis patients. Cell wall deficient bacteria, a term often used interchangeably with l-form, were isolated from 74.2% of psoriasis patients, 23.5% of chronic tonsillitis patients and only 6.3% of controls.(({{pubmed>long:20137493}}))
+  * **differences in microbiota between psoriasis and normal skin** – A 2008 study of psoriatic skin not only found 84 novel species never before known to persist in skin, but also double the proportion of microbes from the //Firmicutes// phylum in psoriatic patients, as compared to healthy controls.(({{pubmed>long:18648509}})) In contrast, Fahlén's study analyzed 10 psoriatic patients using pyrosequencing,(({{pubmed>long:22065152}})) finding no difference in levels of Firmicutes but confirmed lower levels of //Propionibacterium//. The discrepancies between these two studies illustrate the importance of focusing on the [[home:pathogenesis:microbiota#effect_of_bacteria_on_their_human_host|activity of microbes]] and as well as the competence of the immune response.
+  * **bacterial DNA in blood of psoriatic patients** – Peripheral blood samples from 20 patients with psoriasis and from 16 control subjects were studied for the presence of bacteria by PCR using universal 16S ribosomal DNA primers and specific primers for S. pyogenes. Sequence analysis of amplified 16S rRNA sequences was used to determine taxonomic identity. Ribosomal bacterial DNA was detected in the blood of all 20 patients with psoriasis, but in none of the controls.(({{pubmed>long:20607546}}))
-Superantigens(({{pubmed>long:11040420}}))
-microorganisms and psoriasis(({{pubmed>long:8040907}}))
-(({{pubmed>long:18648509}}))
+===== Other treatments =====
+For many physicians, immunosuppressive medications are a first-line treatment for psoriasis. These drugs suppress the innate immune response, which provides some patients with temporary symptom palliation, because they reduce immunopathology, the bacterial die-off reaction.
+  * **corticosteroids** – For even short periods of time, steroid use can become genuinely addictive. Research shows that any kind of short-term symptomatic improvement from corticosteroid use does not last, and that over the longer term, use of the drugs entales a litany of side effects. For their own safety, patients on the Marshall Protocol (MP) must [[home:othertreatments:corticosteroids:weaningoffsteroids|wean off]] of them as opposed to discontinuing them outright.
+  * **TNF-alpha inhibitors** – Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance.(({{pubmed>long:16331857}})) TNF-alpha inhibitors, also known as TNF blockers, anti-TNF drugs or TNF-alpha antagonists, are drugs which interfere with the body's production of TNF-alpha.(({{pubmed>long: 18387510}})) Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects such as increase risk of serious infection such as mycobacterial infection.(({{pubmed>long:16705109}})) (({{pubmed>long:12614731}}))
+  * **methotrexate** – Methotrexate (MTX) is an antibiotic that interferes with bacteria's ability to synthesize folate. It is used to treat diseases with rapid cell growth such as cancer and some autoimmune diseases, particularly the rheumatic diseases. A superior alternative to MTX is the Marshall Protocol antibiotic, Bactrim DS.
+  * **[[home:othertreatments:sunshine|light therapy]]** – Phototherapy suppresses immunity which can lead to the progression of other infections such as human papilloma virus (HPV). A 2010 study used a nested polymerase chain reaction, to analyze skin biopsies taken a from 20 psoriasis patients under phototherapy (UVB) and 20 untreated psoriatic patients. The authors were able to detect viruses in 60% of the treatment but in none of the controls.(({{pubmed>long:20415738}})) In reality, light therapy does nothing to resolve underlying disease state and can actually delay progress for MP patients. Certainly prolonged light exposure has been shown to increase skin melanoma – the World Health Organization now categorizes tanning beds under the highest cancer risk category.(({{pubmed>long:19655431}})) MP patients who have completed the treatment have been able to attest to the fact that sunshine is not necessary for good health or happiness.
-[{{ :home:diseases:2010-proal-slovenia.002.jpg|}}]
 =====  Patient interviews  =====
@@ Line 56: / Line 75: @@
-{{tag>diseases incomplete}}
+{{tag>diseases}}
 ===== Notes and comments =====
-<DiseaseHierarchy>
-GETCONTENT
-  * legacy content
-  *
 ===== References =====

home/diseases/psoriasis.txt · Last modified: 09.14.2022 by 127.0.0.1